Journal
CLINICS IN CHEST MEDICINE
Volume 40, Issue 4, Pages 811-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2019.08.001
Keywords
Tuberculosis; Bedaquiline; Delamanid; Pretomanid; New drugs; Pharmacology
Categories
Funding
- National Institutes of Health [T32 -A1007291-27]
- NIH
- FDA
Ask authors/readers for more resources
Tuberculosis (TB) has now surpassed HIV as the leading infectious cause of death, and treatment success rates are declining. Multidrug-resistant TB, extensively drug-resistant TB, and even totally drug-resistant TB threaten to further destabilize disease control efforts. The second wave in TB drug development, which includes the diarylquinoline, bedaquiline, and the nitroimidazoles delamanid and pretomanid, may offer options for simpler, shorter, and potentially all-oral regimens to treat drug-resistant TB. The third wave of TB drug development includes numerous promising compounds, including less toxic versions of older drug classes and candidates with novel mechanisms of action.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available